Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 910
PxPulse: The Votes are In — What’s next for the US’ role in global health and HIV prevention
In the days ahead under a new US Presidential Administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention. And there will be major implications for the global AIDS response.
Prevention Option:
Dapivirine Vaginal Ring Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:
Cabotegravir Regulatory Approval
Regulatory approvals and those pending for cabotegravir as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:
Dapivirine Vaginal Ring Volume
DVR supply available to low- and middle-income countries as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:
Cabotegravir Volume
Allocation of non-commercial cabotegravir for PrEP supply in low- and middle-income countries, 2023-2026, as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on...
Prevention Option:
Dapivirine Vaginal Ring Implementation
Ongoing and planned implementation studies for the dapivirine vaginal ring as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:
Cabotegravir Implementation
Implementation studies completed, ongoing, or planned for cabotegravir as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:
PrEP Price Comparison
Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:
STIWatch Newsletter, November 2024
The past few months have brought exciting developments in the field of Sexually Transmitted Infections (STIs). The World Health Organization released the global priorities for STIs, which included the need to develop low-cost, rapid, STI...
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
showing 1-10 of 910